NO20090304L - Fremgangsmater for a attenuere frigjoringen av inflammatoriske mediatorer og nyttige peptider - Google Patents

Fremgangsmater for a attenuere frigjoringen av inflammatoriske mediatorer og nyttige peptider

Info

Publication number
NO20090304L
NO20090304L NO20090304A NO20090304A NO20090304L NO 20090304 L NO20090304 L NO 20090304L NO 20090304 A NO20090304 A NO 20090304A NO 20090304 A NO20090304 A NO 20090304A NO 20090304 L NO20090304 L NO 20090304L
Authority
NO
Norway
Prior art keywords
release
inflammatory mediators
present
methods
inhibiting
Prior art date
Application number
NO20090304A
Other languages
English (en)
Norwegian (no)
Inventor
Indu Parikh
Original Assignee
Biomarck Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarck Pharmaceuticals Ltd filed Critical Biomarck Pharmaceuticals Ltd
Publication of NO20090304L publication Critical patent/NO20090304L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
NO20090304A 2006-07-26 2009-01-20 Fremgangsmater for a attenuere frigjoringen av inflammatoriske mediatorer og nyttige peptider NO20090304L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83323906P 2006-07-26 2006-07-26
PCT/US2007/074514 WO2008014414A2 (en) 2006-07-26 2007-07-26 Methods for attenuating release of inflammatory mediators and peptides useful therein

Publications (1)

Publication Number Publication Date
NO20090304L true NO20090304L (no) 2009-04-21

Family

ID=38982357

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090304A NO20090304L (no) 2006-07-26 2009-01-20 Fremgangsmater for a attenuere frigjoringen av inflammatoriske mediatorer og nyttige peptider

Country Status (21)

Country Link
US (6) US8999915B2 (he)
EP (2) EP2053915B1 (he)
JP (2) JP5378998B2 (he)
KR (1) KR101599894B1 (he)
CN (2) CN101516190B (he)
AU (1) AU2007279193B2 (he)
BR (1) BRPI0714953A2 (he)
CA (2) CA2658949C (he)
DK (2) DK2053915T3 (he)
ES (2) ES2488092T3 (he)
HR (1) HRP20140587T1 (he)
IL (1) IL196667A (he)
MX (1) MX2009000975A (he)
NO (1) NO20090304L (he)
PL (2) PL2053915T3 (he)
PT (1) PT2053915E (he)
RU (1) RU2423376C2 (he)
SG (2) SG173411A1 (he)
SI (1) SI2053915T1 (he)
WO (1) WO2008014414A2 (he)
ZA (1) ZA200900550B (he)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2399599A3 (en) 2005-01-20 2012-04-18 Biomarck Pharmaceuticals, Ltd. Mucin hypersecretion inhibitors and methods of use
CN101516190B (zh) 2006-07-26 2014-06-11 拜欧马克医药有限公司 减少炎症介质释放的方法和可用于该方法的肽
WO2010151699A1 (en) * 2009-06-25 2010-12-29 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
WO2011060349A1 (en) * 2009-11-13 2011-05-19 North Carolina State University Methods of modulating mesenchymal stem cells
HUE043971T2 (hu) 2013-04-05 2019-09-30 Biomarck Pharmaceuticals Ltd Egy fûtõrendszer mûködtetési eljárása, fûtõrendszer és felhasználásai
WO2015013669A1 (en) 2013-07-26 2015-01-29 The Regents Of The University Of California Mps peptides and use thereof
US10314889B2 (en) 2013-12-20 2019-06-11 The Regents Of The University Of California Suppression of allergic lung inflammation and hyperreactivity
KR102181548B1 (ko) * 2019-02-20 2020-11-20 한국외국어대학교 연구산학협력단 염증성 질환 또는 자가면역성 질환의 예방 또는 치료 활성을 갖는 펩타이드 및 이의 용도
JP2022527133A (ja) 2019-04-12 2022-05-30 リップタイド バイオサイエンス インコーポレイテッド マクロファージの活性を調節する方法
EP3982928A4 (en) 2019-06-17 2023-07-19 Biomarck Pharmaceuticals, Ltd. PEPTIDES AND METHODS FOR THEIR USE IN THE TREATMENT OF UVEITIS
EP4475866A4 (en) * 2022-02-07 2026-02-25 Park Strategic Ventures Llc Peptides and their methods of use in the treatment of eye disorders
US20250262272A1 (en) * 2022-04-25 2025-08-21 Park Strategic Ventures Llc Peptides and methods of use thereof in treating skin diseases
CN116375796A (zh) * 2022-11-24 2023-07-04 华南农业大学 一种来源于珍珠贝的抗炎肽及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61265341A (ja) * 1985-05-17 1986-11-25 Kawasaki Heavy Ind Ltd Ｖ型エンジンのシリンダ−ブロツク構造
US4873346A (en) 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
US4753945A (en) 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US4966848A (en) * 1988-02-08 1990-10-30 The General Hospital Corporation Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase
CA2003316A1 (en) 1988-11-18 1990-05-18 John F. Oram Hdl-binding proteins
US5223421A (en) * 1989-10-25 1993-06-29 The General Hospital Corporation Identification of methionine Nα-acetyltransferase
WO1992005784A1 (en) 1990-10-02 1992-04-16 Warner-Lambert Company 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
US5292498A (en) 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
WO1993000353A1 (en) 1991-06-20 1993-01-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sequences characteristic of human gene transcription product
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
EP0551200A1 (en) 1992-01-07 1993-07-14 National University Of Singapore Protein phosphatase inhibitors for use in therapy
US5298506A (en) 1992-05-08 1994-03-29 Brigham And Women's Hospital Use of guanylate cyclase inhibitors in the treatment of shock
US5861502A (en) 1992-11-09 1999-01-19 Thomas Jefferson University Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen
US5512269A (en) 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US5858981A (en) 1993-09-30 1999-01-12 University Of Pennsylvania Method of inhibiting phagocytosis
US5436243A (en) 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
EP0759768A4 (en) 1994-04-07 2000-08-09 Proteinix Company VASOACTIVE COLON PEPTIDE
US5985822A (en) 1994-12-09 1999-11-16 The Scripps Research Institute Inhibition of glial cell proliferation with N-CAM homophilic peptides
US6713605B1 (en) 1996-04-10 2004-03-30 Kansas State University Research Foundation Synthetic peptides that inhibit leukocyte superoxide anion production and/or attract leukocytes
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
GB9620390D0 (en) 1996-09-30 1996-11-13 Eisai London Res Lab Ltd Substances and their uses
DE19716713A1 (de) 1997-04-21 1998-10-22 Paz Arzneimittelentwicklung Arzneimittel, enthaltend Ibuprofenthioester als Hemmer der Nf-kappaB abhängigen Bildung von Mediatoren von Entzündung und Schmerz
EP1154786B1 (en) 1999-02-24 2004-10-13 North Carolina State University Compositions for altering mucus secretion
US8501911B2 (en) 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
US7544772B2 (en) * 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US6245320B1 (en) 1999-09-01 2001-06-12 University Of Maryland Inhibition of mucin release from airway goblet cells by polycationic peptides
AU7709300A (en) 1999-09-24 2001-04-24 Linden Technologies, Inc. Drug discovery using gene expression profiling
ATE245639T1 (de) 1999-12-03 2003-08-15 Pfizer Prod Inc Acetylenderivate zur verwendung als schmerzstillendes oder entzündungshemmendes mittel
US7919469B2 (en) 2000-02-24 2011-04-05 North Carolina State University Methods and compositions for altering mucus secretion
US7265088B1 (en) 2000-02-24 2007-09-04 North Carolina State University Method and compositions for altering mucus secretion
AU2002322475B2 (en) 2001-06-26 2008-02-21 North Carolina State University Blocking peptide for inflammatory cell secretion
JP2004049133A (ja) 2002-07-22 2004-02-19 Kumamoto Technology & Industry Foundation Ｎ−ミリストイルトランスフェラーゼ活性の測定方法
WO2006023312A2 (en) 2004-08-20 2006-03-02 Carl Deirmengian Diagnostic assay for source of inflammation
US7408030B2 (en) 2005-01-13 2008-08-05 North Carolina State University Purification of immunoglobulins using affinity chromatography and peptide ligands
EP2399599A3 (en) 2005-01-20 2012-04-18 Biomarck Pharmaceuticals, Ltd. Mucin hypersecretion inhibitors and methods of use
CN101516190B (zh) 2006-07-26 2014-06-11 拜欧马克医药有限公司 减少炎症介质释放的方法和可用于该方法的肽

Also Published As

Publication number Publication date
JP2009544737A (ja) 2009-12-17
JP2013241428A (ja) 2013-12-05
JP5819889B2 (ja) 2015-11-24
EP2053915A2 (en) 2009-05-06
EP2722052B1 (en) 2019-03-20
US9827287B2 (en) 2017-11-28
ZA200900550B (en) 2010-03-31
US20200138898A1 (en) 2020-05-07
CA2842219C (en) 2017-07-11
US8999915B2 (en) 2015-04-07
AU2007279193A1 (en) 2008-01-31
CN101516190A (zh) 2009-08-26
US20210260154A1 (en) 2021-08-26
DK2053915T3 (da) 2014-06-30
RU2423376C2 (ru) 2011-07-10
ES2488092T3 (es) 2014-08-26
EP2053915A4 (en) 2011-06-08
US20090203620A1 (en) 2009-08-13
CN103990111B (zh) 2016-08-31
JP5378998B2 (ja) 2013-12-25
SG10201500418QA (en) 2015-03-30
SG173411A1 (en) 2011-08-29
KR101599894B1 (ko) 2016-03-04
SI2053915T1 (sl) 2014-10-30
BRPI0714953A2 (pt) 2013-07-16
MX2009000975A (es) 2009-04-07
ES2725599T3 (es) 2019-09-25
HK1201190A1 (en) 2015-08-28
US20180036367A1 (en) 2018-02-08
HRP20140587T1 (hr) 2014-11-21
RU2009106673A (ru) 2010-09-10
PT2053915E (pt) 2014-08-25
CA2658949A1 (en) 2008-01-31
IL196667A0 (en) 2011-08-01
WO2008014414A2 (en) 2008-01-31
EP2722052A1 (en) 2014-04-23
DK2722052T3 (en) 2019-04-29
US20160030509A1 (en) 2016-02-04
CA2658949C (en) 2014-04-22
CA2842219A1 (en) 2008-01-31
CN101516190B (zh) 2014-06-11
KR20090037487A (ko) 2009-04-15
WO2008014414A3 (en) 2008-09-25
PL2053915T3 (pl) 2014-12-31
US20230293629A1 (en) 2023-09-21
AU2007279193B2 (en) 2011-12-01
PL2722052T3 (pl) 2019-08-30
HK1125793A1 (en) 2009-08-21
CN103990111A (zh) 2014-08-20
IL196667A (he) 2017-04-30
EP2053915B1 (en) 2014-06-11

Similar Documents

Publication Publication Date Title
NO20090304L (no) Fremgangsmater for a attenuere frigjoringen av inflammatoriske mediatorer og nyttige peptider
WO2007103368A3 (en) Methods for regulating inflammatory mediators and peptides useful therein
WO2010151799A3 (en) Compounds for modulating rna binding proteins and uses therefor
WO2009043889A3 (en) Oxadiazole derivatives
WO2011019986A3 (en) Processes for preparing pemetrexed
DK1948789T3 (da) Fremgangsmåde til fremstilling af permanente, humane cellelinjer
IN2012DN00338A (he)
WO2008118332A3 (en) Hydrazido-peptides as inhibitors of hcv ns3-protease
WO2008024175A3 (en) Kernel fractionation system
WO2006023844A3 (en) Compositions and methods comprising proteinase activated receptor antagonists
WO2006065480A3 (en) Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control
WO2012097238A3 (en) Il-27 antagonists for treating inflammatory diseases
WO2007130860A3 (en) Constrained compounds as cgrp-receptor antagonists
BRPI1007870A2 (pt) Bactéria isolada, método para produzir etanol, kit, cepa de e. Coli ly180, etanol, microarranjo, promotor de yqhd isolado, e, uso do promotor de yqhd.
SG171601A1 (en) Further medical uses of antisecretory protein
WO2008137122A3 (en) Inducing premature senescence to stabilize stem cell feeder layer cells
WO2007082177A3 (en) Myeloid suppressor cells, methods for preparing them, and methods for using them for treating autoimmunity
WO2007134846A3 (en) Process for purification of anastrozole
WO2008140641A3 (en) Pure paliperidone and processes for preparing thereof
MX2008013777A (es) Usos medicos adicionales de la proteina antisecretora.
WO2008134665A8 (en) Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
WO2008021346A3 (en) Pure paliperidone and processes for preparing thereof
WO2007130927A3 (en) Condensed tricyclic compounds as cgrp-receptor antagonists
WO2007018671A3 (en) Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
WO2009126335A3 (en) Ant2 inhibitor compounds and methods of use thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application